about
Platelets: still a therapeutical target for haemostatic disorders.Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiographyPotent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel ResistanceSpecies Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel.Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis.Anti-platelet therapy in small animal medicine.Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials.P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation.Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel.Clopidogrel Response Variability in Unruptured Intracranial Aneurysm Patients Treated with Stent-Assisted Endovascular Coil Embolization : Is Follow-Up Clopidogrel Response Test Necessary?The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
P2860
Q34486685-8D024446-81B7-4A04-9C9C-3DA73010535AQ36709544-BD080C2E-26DF-4B92-BAFF-8D5C52335F5BQ37204050-FBFBBE87-7DF5-44E6-AC5E-A784D6C080C2Q37319541-D0C1F598-7472-441C-BFB8-A96F0F68D124Q38216499-51E18DD1-46B7-45D0-BD6D-AB0F9FC08B09Q38396605-694D21D6-5594-4A84-9F41-3E3DDB4ECDBCQ38770733-DFCADE5E-712F-4459-81C3-6246FB6649BCQ38817051-595AE847-383A-4ED4-9FB7-15C5DDBFF763Q41511099-BFFED773-775D-4278-8142-8180925F4E24Q51541681-CC946355-37FC-41F6-9A16-F9F834E76071Q51547504-0BB8E78D-2D7F-4BAB-980A-5274535DF27DQ53079748-25A76C55-D818-48E5-8B98-E08FFE4C21F0Q54627886-D4D82762-6E77-4395-A4F1-DFF4E500117B
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Clopidogrel "resistance": where are we now?
@ast
Clopidogrel "resistance": where are we now?
@en
Clopidogrel "resistance": where are we now?
@nl
type
label
Clopidogrel "resistance": where are we now?
@ast
Clopidogrel "resistance": where are we now?
@en
Clopidogrel "resistance": where are we now?
@nl
prefLabel
Clopidogrel "resistance": where are we now?
@ast
Clopidogrel "resistance": where are we now?
@en
Clopidogrel "resistance": where are we now?
@nl
P2860
P1476
Clopidogrel "resistance": where are we now?
@en
P2093
Alex R Hobson
Zeshan Qureshi
P2860
P356
10.1111/J.1755-5922.2011.00296.X
P577
2011-08-03T00:00:00Z